Bringing the fundamentals into focus…
Back to BioCryst Pharmaceuticals, Inc.
How BioCryst Pharmaceuticals, Inc. stacks up
BCRX · against 386 other Healthcare companies of similar size
Profitability
22/ 100
Near the bottom of its peers.
Ranked #310 of 387 · scores higher than 19% of peers
Bars: peers in each 10-point band of the profitability score31 peers with a profitability score of 20–29, including BCRX · Click a bar to see the companies
Why profitability scores 22?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on assets and operating margin, which are weaker than most Healthcare peers.
- a lower return on assets: weaker than 96% of peers. Return on assets: -69.0% vs peer median 1.7%
- a thinner operating margin: weaker than 81% of peers. Operating margin: -33.3% vs peer median 7.1%
- a higher return on invested capital: stronger than 100% of peers. Return on invested capital: 1147.3% vs peer median 4.7%
Metric by metric
Position: dot = BCRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | BCRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 364 reported | 1147.3% | 6.1% | 100% | 33% | |
| Operating marginHigher is better · 357 reported | -33.3% | 8.5% | 15% | 33% | |
| Return on assetsHigher is better · 371 reported | -69.0% | 2.1% | 2% | 33% | |
| Return on equityHigher is better · 356 reported | Not reported | 5.2% | — | — | Context only |
| Gross marginHigher is better · 400 reported | 77.4% | 49.1% | 86% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around BCRX| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 5 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 305 | 1.5B USD | 24 | 44 | |
| 305 | 2.0B USD | 24 | 42 | |
| 308 | 14.2B CNY (≈$2.0B) | 23 | 10 | |
| 308 | 4.2B USD | 23 | 44 | |
| 310 | 2.2B USD | 22 | 32 | |
| 310 | 4.1B USD | 22 | 42 | |
| 310 | 1.6B USD | 22 | 30 | |
| 310 | 1.1B USD | 22 | 46 | |
| 310 | 2.0B USD | 22 | 29 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score